Amgen | AMGN - Gross Profit On Sales

Stock Price
384.12
Daily Change
16.32 4.44%
Monthly
12.43%
Yearly
30.86%
Q1 Forecast
331.35

Amgen reported $6.48B in Gross Profit on Sales for its fiscal quarter ending in September of 2025.





Gross Profit On Sales Change Date
AbbVie USD 10.47B 605M Sep/2025
Agios Pharmaceuticals USD 11.2M 448K Sep/2025
ALKERMES USD 265.83M 8.06M Sep/2025
Amgen USD 6.48B 307M Sep/2025
Biogen USD 1.65B 34.6M Dec/2025
BioMarin Pharmaceutical USD 631.2M 39.27M Sep/2025
Bristol-Myers Squibb USD 8.79B 110M Sep/2025
Eli Lilly USD 14.59B 1.48B Sep/2025
Exelixis USD 579.18M 30.39M Sep/2025
Genmab DKK 868M 195M Jun/2025
Gilead Sciences USD 5.58B 453M Jun/2025
GlaxoSmithKline GBP 6.18B 106M Dec/2025
Glaxosmithkline GBP 8.75B 2.92B Sep/2025
Incyte USD 1.27B 130.22M Sep/2025
Ionis Pharmaceuticals USD 155M 293M Sep/2025
J&J USD 16.6B 118M Dec/2025
Merck USD 13.42B 431M Sep/2025
Moderna USD 809M 791M Sep/2025
Neurocrine Biosciences USD 780.9M 104.7M Sep/2025
Novartis USD 10.82B 695M Sep/2025
Novartis USD 10.82B 694M Sep/2025
Pfizer USD 3.54B 7.61B Sep/2025
PTC Therapeutics USD 187.69M 24.3M Sep/2025
Regeneron Pharmaceuticals USD 3.3B 67M Dec/2025
Roche Holding CHF 22.09B 10.04B Dec/2025
Sanofi EUR 8.45B 1.31B Dec/2025
Sarepta Therapeutics USD 247.9M 209.96M Sep/2025
Takeda JPY 790.55B 262.97B Dec/2025
Teva Pharmaceutical Industries USD 2.66B 351M Dec/2025
Ultragenyx Pharmaceutical USD 131.94M 11.55M Sep/2025
Vertex Pharmaceuticals USD 2.66B 104.4M Sep/2025